Angiotensin converting enzyme and methylenetetrahydrofolate reductase gene variations in fibromyalgia syndrome

Inanir, Ahmet; Yığıt, Serbülent; Tekcan, Akın; Pınarlı, Ferda Alpaslan; Inanir, Sema; Karakuş, Nevin

doi:10.1016/j.gene.2015.03.051

Cited by 15 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, after isolated, the DNA should be stored at -20C. ACE gene I/D polymorphism genotypes were determined by polymerase chain reaction (PCR) using the primers and conditions described earlier 8,11 . Reactions were performed with 10 pmol of each primer: sense oligo, 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' , and antisense oligo, 5'-GAT GTG GCC ATC ACA TTC GTC AAG T-3' .…”

Section: Genotype Determinationmentioning

confidence: 99%

“…Angiotensin II is a peptide hormone which acts as a stimulator of proinflammatory cytokines and interferes with hypothalamic-pituitary-adrenal (HPA) axis activation in response to stress 5,10 . It is mentioned from the effect of the brain renin-angiotensin system in regulation of mood 11 . It has been stated that ACE I/D polymorphism may be associated with suicide and MDD 5 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between major depressive disorder and ACE gene I/D polymorphism in a Turkish population

Inanir¹,

Yığıt²,

Celikel³

et al. 2016

Arch. Clin. Psychiatry (São Paulo)

Self Cite

View full text Add to dashboard Cite

Background: Major depressive disorder (MDD) is a complex disease and a significant health problem that is prevalent across the world. Angiotensin-converting enzyme (ACE) has an important role in renin-angiotensin system (RAS) and converts inactive angiotensin I to a potent vasopressor and aldosterone-stimulating peptide angiotensin II. Levels of ACE in plasma vary according to the insertion/deletion (I/D) polymorphism of ACE gene. Objective: The aim of the current study was to examine the influence ACE gene I/D variations on the risk of MDD. Methods: In the present case-control study, we analyzed ACE I/D polymorphism in 346 MDD patients and 210 healthy subjects using polymerase chain reaction technique. Results: Comparing the two groups, no significant difference was observed with regard to either genotype distributions or allele frequencies of the I/D polymorphism of ACE gene. Discussion: Our findings suggest that the ACE I/D polymorphism is not associated with MDD in Turkish case-control study. Further studies are still needed.

show abstract

Section: Genotype Determinationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Relationship between major depressive disorder and ACE gene I/D polymorphism in a Turkish population

Inanir¹,

Yığıt²,

Celikel³

et al. 2016

Arch. Clin. Psychiatry (São Paulo)

Self Cite

View full text Add to dashboard Cite

show abstract

“…The first study published in the literature investigating the relationship between FMS and MTHFR C677T was performed by Inanir et al [26]. This study, conducted among Turkish patients, showed that there was no significant correlation between MTHFR C677T mutation and FMS, but that MTHFR C677T mutation was significantly associated with findings of dry eye and feelings of stiffness.…”

Section: Discussionmentioning

confidence: 99%

Association between fibromyalgia syndrome and MTHFR C677T genotype in Turkish patients

Ahi¹,

Afşar²,

Sözay³

et al. 2020

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Committee on 09/01/2013 (Project no: KA12 / 274). All procedures in this study involving human participants were performed in accordance with the 1964 Helsinki Declaration and its later amendments. Etik Kurul Onayı: Bu çalışma 09/01/2013 tarihinde Başkent Üniversitesi "Tıp ve Sağlık Bilimleri Araştırma Kurulu" ve "Etik Kurul" (Proje no: KA12/274) tarafından onaylanmıştır. İnsan katılımcıların katıldığı çalışmalardaki tüm prosedürler, 1964 Helsinki Deklarasyonu ve daha sonra yapılan değişiklikler uyarınca gerçekleştirilmiştir.

show abstract

“…Other associated genes involved in the susceptibilities of FM are: Dopamine receptor D4 ( DRD4 ), monoamine oxidase ( MAO-A ), β-2 adrenergic receptor, guanosine triphosphate cyclohydrolase ( GTPCH ) (involved in the dopamine, serotonin, and nitric oxide production), γ-aminobutyric acid ( GABA ), a receptor β3 subunit ( GABRB3 ); sodium channel NaV1.7 ( SCN9A ); apolipoprotein ( APOE ); myelin transcription factor 1-like ( MYT1L ) (involved in neuronal differentiation) and neurexin ( NRXN3 ), a synaptic scaffolding stabilizer in glutamate and GABA neurotransmission [ 12 ]. Additionally, Inanir et al studied the angiotensin converting enzyme ( ACE ) and methylenetetrahydrofolate reductase ( MTHFR ) gene polymorphisms in 200 FM Turkish patients [ 13 ]. The authors concluded that ACE I/D polymorphisms are associated with an increased susceptibility for FM.…”

Section: Genetic Polymorphisms Influence On Chronic Pain Conditionmentioning

confidence: 99%

“…The authors concluded that ACE I/D polymorphisms are associated with an increased susceptibility for FM. In addition, it was determined that MTHFR C677T polymorphisms were associated with symptoms of stiffness and xerophthalmia [ 13 ].…”

Section: Genetic Polymorphisms Influence On Chronic Pain Conditionmentioning

confidence: 99%

The Role of Genetic Polymorphisms in Chronic Pain Patients

Knežević

Tverdohleb

Knezevic

et al. 2018

IJMS

View full text Add to dashboard Cite

It is estimated that the total annual financial cost for pain management in the U.S. exceeds 100 billion dollars. However, when indirect costs are included, such as functional disability and reduction in working hours, the cost can reach more than 300 billion dollars. In chronic pain patients, the role of pharmacogenetics is determined by genetic effects on various pain types, as well as the genetic effect on drug safety and efficacy. In this review article, we discuss genetic polymorphisms present in different types of chronic pain, such as fibromyalgia, low back pain, migraine, painful peripheral diabetic neuropathy and trigeminal neuralgia. Furthermore, we discuss the role of CYP450 enzymes involved in metabolism of drugs, which have been used for treatment of chronic pain (amitriptyline, duloxetine, opioids, etc.). We also discuss how pharmacogenetics can be applied towards improving drug efficacy, shortening the time required to achieve therapeutic outcomes, reducing risks of side effects, and reducing medical costs and reliance upon polypharmacy.

show abstract

Angiotensin converting enzyme and methylenetetrahydrofolate reductase gene variations in fibromyalgia syndrome

Cited by 15 publications

References 30 publications

Relationship between major depressive disorder and ACE gene I/D polymorphism in a Turkish population

Relationship between major depressive disorder and ACE gene I/D polymorphism in a Turkish population

Association between fibromyalgia syndrome and MTHFR C677T genotype in Turkish patients

The Role of Genetic Polymorphisms in Chronic Pain Patients

Contact Info

Product

Resources

About